Walgreens Concludes Public Trading Chapter with Landmark Private Equity Acquisition

The era of Walgreens Boots Alliance as a publicly traded entity has drawn to a close. The pharmacy giant has been formally acquired by private equity firm Sycamore Partners in a monumental deal, culminating in its delisting from the Nasdaq exchange. This transition ushers in a new period of strategic overhaul under private ownership, free from the scrutiny of public markets.

New Leadership Signals Strategic Intent

In a move that aligns with the ownership change, Walgreens has appointed a new chief executive. Mike Motz, a seasoned retail executive and former head of Staples US Retail—another Sycamore portfolio company—has assumed the role of CEO with immediate effect. His appointment strongly indicates a strategic pivot towards revitalizing the company’s core retail and pharmacy operations. The outgoing CEO, Tim Wentworth, will maintain a connection to the business, transitioning to a director role.

Deal Structure and Key Figures

The acquisition, valued at approximately $23.7 billion, was finalized in late August 2025. Shareholders received a cash payment of $11.45 per share. The transaction also includes a contingent value right, offering the potential for an additional future payout of up to $3.00 per share, which is tied to the eventual divestiture of assets belonging to the VillageMD healthcare unit. Notably, former CEO Stefano Pessina and his family reinvested their entire stake in the deal, marking a significant vote of confidence in the company’s future trajectory.

Should investors sell immediately? Or is it worth buying Walgreens?

Operational Challenges Precipitate Change

The decision to go private follows a period of pronounced operational strain for the retailer. Its final quarterly earnings report as a public company laid bare the underlying pressures:

• The company posted a quarterly loss of $175 million, despite a 7% increase in revenue, which reached $39 billion.
• Comparable retail sales experienced a decline of 2.4%.
• In response to these financial headwinds, a plan was initiated to shutter 1,200 underperforming stores.

The Path Forward as a Private Entity

Operating away from the public eye is expected to facilitate a swifter and more profound corporate restructuring. A renewed emphasis on operational discipline and a customer-centric retail strategy is anticipated. This private status will likely enable an accelerated program that could involve further store closures and aggressive cost-cutting measures. Strategic moves, such as the potential spin-off of healthcare divisions like VillageMD, are considered probable as the new ownership seeks to restore profitability.

With its delisting complete, Walgreens and its associated holdings, including The Boots Group and VillageMD, are poised to operate as more agile, distinct entities. Sycamore Partners is betting that a private environment will provide the necessary stability to manage the company’s substantial debt and execute a turnaround strategy designed to create significant long-term value.